---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-112139"
form_type: "8-K"
ticker: "SRPT"
cik: "0000873303"
company_name: "Sarepta Therapeutics, Inc."
filed_at: "2022-04-21T23:59:59+00:00"
generated_at: "2026-06-26T05:58:20.762353+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sarepta amends CEO Ingram's stock option; 33% vests immediately; new targets to 2025

## Summary
- 33.33% (1,099,890 shares) of performance option vested effective April 19, 2022; remainder eligible through June 26, 2025.
- Unvested portion triggers at stock prices $105.74, $128.65, $155.37, $186.36, requiring relative CAGR vs Biotech Index.
- New one-year holding period on shares acquired upon exercise, except for change in control, death, disability, or certain terminations.
- Change-in-control vesting requires minimum $130/share sale price if within 18 months; else next column applies.
- Company expects significant non-cash accounting charge for the amendment; to be disclosed in upcoming 10-Q.

## SEC filing metadata
- accession: 0001193125-22-112139
- form_type: 8-K
- ticker: SRPT
- cik: 0000873303
- company_name: Sarepta Therapeutics, Inc.
- filed_at: 2022-04-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/873303/000119312522112139/0001193125-22-112139-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/873303/000119312522112139/d329540d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-112139
- JSON: https://secwatch.observer/filing/0001193125-22-112139.json
- Plain text: https://secwatch.observer/filing/0001193125-22-112139.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.